BriaCell Therapeutics (FRA:8BT0) Long-Term Capital Lease Obligation : €0.00 Mil (As of Jan. 2025)

View and export this data going back to 2015. Start your Free Trial

What is BriaCell Therapeutics Long-Term Capital Lease Obligation?

BriaCell Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Jan. 2025 was €0.00 Mil.

BriaCell Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for BriaCell Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BriaCell Therapeutics Long-Term Capital Lease Obligation Chart

BriaCell Therapeutics Annual Data

Trend

Jul15

Jul16

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

BriaCell Therapeutics Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	-	-	-	-

BriaCell Therapeutics (FRA:8BT0) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

BriaCell Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of BriaCell Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

BriaCell Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (FRA:8BT0) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

BCTX:USA BCT:Canada

Address

235-15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1

Website

https://www.briacell.com

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

BriaCell Therapeutics Headlines

No Headlines